Kadans expands its presence in the United Kingdom by adding its second research hub in the country to its Pan-European science park portfolio.
Kadans acquired Sycamore House from GSK. It is a 9,640 sqm industrial and warehouse building, located directly adjacent to Stevenage Bioscience Catalyst (“SBC”), and the Cell and Gene Therapy Catapult Manufacturing Centre (“CGTCMC”). Kadans will redevelop and extend Sycamore House into a modern, vibrant, multi-tenanted R&D facility with expected completion mid-2021.